HERTFORDSHIRE, England, and PITTSBURGH, May 18, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced four scientific abstracts from the Wixela™ Inhub™ ...
Mylan N.V. MYL received a significant boost when the FDA approved its generic version of GlaxoSmithKline's GSK Advair Diskus - Wixela Inhub - following a few setbacks. Notably, this is the first ...
wixela-product-image Wixela Inhub (fluticasone propionate and salmeterol inhalation powder), the first substitutable generic of Advair Diskus (GlaxoSmithKline), has been made available by Mylan Mylan ...
HERTFORDSHIRE, England and PITTSBURGH, Jan. 31, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced the U.S. Food and Drug Administration (FDA) approval of Wixela™ Inhub™ (fluticasone ...
If Mylan’s aggressive pricing for its generic Advair product sounds familiar, that’s because it is. The knockoffs giant set the list price for Wixela Inhub, its copy of GlaxoSmithKline’s respiratory ...
Mylan N.V. MYL received a significant boost when the FDA approved its generic version of GlaxoSmithKline’s GSK Advair Diskus — Wixela Inhub — following a few setbacks. Notably, this is the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback